B-RAF with PLX4032: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
<applet load='3og7' size='800' color='white' frame='true' align='right' caption='testcaption' /> | <applet load='3og7' size='800' color='white' frame='true' align='right' caption='testcaption' /> | ||
<scene name='B-RAF_with_PLX4032/Plx_4032_only/ | <scene name='B-RAF_with_PLX4032/Plx_4032_only/2>PLX 4032</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Atp/ | <scene name='B-RAF_with_PLX4032/Atp/2'>ATP</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Wild-type_b-raf/ | <scene name='B-RAF_with_PLX4032/Wild-type_b-raf/2'>Wild-Type B-RAF</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Mutated_v600e/ | <scene name='B-RAF_with_PLX4032/Mutated_v600e/2'>V600E Mutation</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/H-bond/4'>H-Bond Interaction Asp594 and PLX4032</scene><br> | <scene name='B-RAF_with_PLX4032/H-bond/4'>H-Bond Interaction Asp594 and PLX4032</scene><br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/4'>Superposition overview</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/5'>Superposition close up</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Superposition3og71uwh/ | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/2'>Superposition active site</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-in/1'>Confirmation Change DFG-In</scene> <br> | <scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-in/1'>Confirmation Change DFG-In</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-out/1'>Confirmation Change DFG-Out</scene> | <scene name='B-RAF_with_PLX4032/Confirmation_change_dfg-out/1'>Confirmation Change DFG-Out</scene> | ||
Revision as of 22:06, 7 October 2010
B-RAF with PLX4032B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
